New Study Tests Labeled Sputum in the Diagnosis of Early Stage Lung Cancer

New Study Tests Labeled Sputum in the Diagnosis of Early Stage Lung Cancer

A research study entitled “Early Detection of Lung Cancer with Meso Tetra (4-carboxyphenyl) Porphyrin-Labeled Sputum,” published in the Journal of Thoracic Oncology in September 2015, investigated the effectiveness of the Cypath® test in the detection of lung cancer.

The idea behind the study, funded by bioAffinity Technologies, a privately held biotechnology company specializing in cancer detection, was to see if the CyPath® test could complement CT screening or function as a standalone technique for the detection of lung cancer in its early stages.

The proprietary technology created by bioAffinity Technologies is based upon labeled porphyrin, a compound that is able to bind to lung cancer cells, allowing them to become fluorescent red when viewed under particular frequencies of light. The study looked at 128 participants, some of which had diagnosed lung cancer and others that were at a higher risk for lung cancer but didn’t  yet have the disease.

According to the principal researcher Dr. Thomas Bauer II, MD, who is the medical director for the Thoracic Oncology division at Meridian Health, each test patient was given the opportunity to provide a deep-lung sample of their sputum that was then mixed with Cytopath® and observed under a special microscope that showed fluoresced red results when cancer cells were present. Dr. Bauer II indicated that, because porphyrins bind specifically to cancer cells, having fluorescent porphyrins as a test for cancer cells was an excellent way to accurately and non-invasively diagnose lung cancer when it is the most able to be treated, in its early stages.

The CyPath®-labeled slides were evaluated along with different patient statistics and were analyzed to decide whether the Cypath® technology was able to accurately determine whether or not cancer cells were present in the cancer patients but not in the non-cancer patients. Researchers observed that the assay, based on fluorescent-labeled porphyrin, was accurate 81 percent of the time in the cancer population, with a 40% false-positive rate and an 83% negative predictive value.

In another study published in the journal New England Journal of Medicine, CT scanning of the lungs for lung cancer revealed a false-positive rate of more than 96 percent, meaning that the two tests together may be able to diagnose lung cancer with a greater degree of accuracy than just one test by itself.

The test is currently being optimized by bioAffinity Technologies along with scientists at the University of Texas Health Science Center in San Antonio, Texas.  The idea behind the optimization protocol is to lead to greater accuracy of  the procedure.

The optimization of the test is designed to bring forth a commercially-available medical product that will be simple to use and aid in the detection of  lung cancer when used alongside the CT scans of the chest.

Leave a Comment